Pulmonary arterial hypertension--contemporary management strategy

Area of Science:

• Cardiology
• Pulmonology
• Pharmacology

Background:

• Pulmonary arterial hypertension (PAH) is a severe chronic disorder of pulmonary arteries.
• It is characterized by progressive precapillary pulmonary hypertension, leading to poor quality of life and a very poor prognosis.
• Without treatment, PAH causes death within 2-3 years of diagnosis and predominantly affects younger women.

Purpose of the Study:

• To review the diagnosis and treatment of Pulmonary Arterial Hypertension (PAH).
• To emphasize the importance of specialized PAH centers for comprehensive patient management.
• To highlight the benefits of a collaborative approach between specialized centers.

Main Methods:

• Literature retrieval using MEDLINE with terms: pulmonary hypertension, PAH, diagnosis, treatment.
• Review of reference citations from identified publications.
• Synthesis of current knowledge on PAH management.

Main Results:

• Novel drugs, including endothelin receptor antagonists, prostanoids, and phosphodiesterase-5 inhibitors, have been tested in randomized trials for specific PAH therapy.
• PAH management necessitates an individualized approach, advanced knowledge, and significant experience.
• Referral to specialized PAH centers is crucial for accurate diagnosis and effective therapy.

Conclusions:

• PAH treatment should be symptomatic and focused on improving patient survival and quality of life.
• A close collaboration between specialized PAH centers enhances patient outcomes.
• Specialized centers provide essential diagnosis and therapy for PAH patients.